GT Biopharma, Inc. (NASDAQ:GTBP) Gets FDA IND for GTB-5550 in Multiple Myeloma
GT Biopharma received FDA IND clearance for GTB-5550 in multiple myeloma under an IST. Trial start depends on non-dilutive grant funding. Unaudited proforma cash is about $11M, expected to fund operations into Q3 2027.Material DetailsContext by AI AnalystGT Biopharma is early clinical stage, expand…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.